Prediction of early recurrence as a marker of surgical futility in pancreatic adenocarcinoma
Open Access
- 5 March 2025
- journal article
- Published by Elsevier in Surgical Oncology
- Vol. 59, 102208
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Predictive factors for early recurrence after pancreaticoduodenectomy in patients with resectable pancreatic head cancer: A multicenter retrospective studySurgery, 2022
- Estimated Projection of US Cancer Incidence and Death to 2040JAMA Network Open, 2021
- Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJAMA Surgery, 2020
- Clinical implications of the serum CA19-9 level in “biological borderline resectability” and “biological downstaging” in the setting of preoperative chemoradiation therapy for pancreatic cancerPancreatology, 2020
- Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinomaEuropean Journal of Cancer, 2020
- Patterns of Recurrence After Resection of Pancreatic Ductal AdenocarcinomaJAMA Surgery, 2019
- Impact of resection margin status on recurrence and survival in pancreatic cancer surgeryBritish Journal of Surgery, 2019
- Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective studyPancreatology, 2015
- Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual TargetsJournal of Gastrointestinal Surgery, 2015